Panic disorder

New Research from the University of Regina and the National Police Federation Reveals Escalating Mental Health Injuries Among RCMP Members

Retrieved on: 
Tuesday, February 27, 2024

OTTAWA, ON, Feb. 27, 2024 /CNW/ - Today, the National Police Federation (NPF) released a new report on mental health among RCMP Members based on a study by a team of researchers at the University of Regina: "Behind the Badge: Revealing Escalating Mental Health Injuries Among RCMP Members".

Key Points: 
  • OTTAWA, ON, Feb. 27, 2024 /CNW/ - Today, the National Police Federation (NPF) released a new report on mental health among RCMP Members based on a study by a team of researchers at the University of Regina: "Behind the Badge: Revealing Escalating Mental Health Injuries Among RCMP Members".
  • This report reveals the escalating mental health challenges amongst Members of the RCMP Members across Canada while providing a pathway for positive change in the way mental health services are provided to Members.
  • Only 6.4% of cadets (RCMP recruits in training) screen positively for any current mental disorders compared to 10.1% for the general population.
  • Members are six times more likely to screen positive for any mental health disorder than the general population.

Aiberry Addresses Growing U.S. Mental Health Needs; Adds Comprehensive Screening Tool Covering Five Major Anxiety Disorders to AI-Powered Assessment Platform

Retrieved on: 
Tuesday, November 14, 2023

The comprehensive anxiety screening includes assessments for five distinct anxiety disorders including generalized anxiety disorder, social anxiety disorder, panic disorder, post traumatic stress syndrome (PTSD), and obsessive compulsive disorder (OCD).

Key Points: 
  • The comprehensive anxiety screening includes assessments for five distinct anxiety disorders including generalized anxiety disorder, social anxiety disorder, panic disorder, post traumatic stress syndrome (PTSD), and obsessive compulsive disorder (OCD).
  • View the full release here: https://www.businesswire.com/news/home/20231114632816/en/
    Aiberry's comprehensive anxiety screening includes assessments for five distinct anxiety disorders within Aiberry's innovative AI-powered platform.
  • (Graphic: Business Wire)
    MedPass, a subscription-based platform powered by HealthBird, focused on proactive health management, is partnering with Aiberry on the expanded platform.
  • Anxiety and mental health are fast becoming a growing issue in the United States with 18% of Americans suffering from anxiety each year , according to the National Institutes of Health.

Movn Health Selected as Winner of Point32Health's Second Innovation Challenge

Retrieved on: 
Tuesday, December 12, 2023

CANTON, Mass., Dec. 12, 2023 /PRNewswire/ -- Point32Health, the parent company of Harvard Pilgrim Health Care and Tufts Health Plan, has announced Movn Health as the winner of its second annual Innovation Challenge.

Key Points: 
  • CANTON, Mass., Dec. 12, 2023 /PRNewswire/ -- Point32Health, the parent company of Harvard Pilgrim Health Care and Tufts Health Plan, has announced Movn Health as the winner of its second annual Innovation Challenge.
  • Based in Irvine, California, Movn Health is a leading telehealth provider for remote cardiac rehab and prevention.
  • In partnership with health plans and providers, Movn helps close cardiovascular care gaps with an evidence-based approach.
  • The other two finalists of the second Innovation Challenge were Cognoa, based in Palo Alto, California, and Curio Digital Therapeutics , based in Princeton, NJ.

The Inner Circle Acknowledges, Katherine A. Daly, MD as a Distinguished Medical Professional for her work in the Pediatrics and Psychiatry Fields.

Retrieved on: 
Monday, December 4, 2023

WAYZATA, Minn., Dec. 4, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Katherine A. Daly, MD, is acknowledged as a Distinguished Medical Professional for her work in the Pediatrics and Psychiatry Fields.

Key Points: 
  • WAYZATA, Minn., Dec. 4, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Katherine A. Daly, MD, is acknowledged as a Distinguished Medical Professional for her work in the Pediatrics and Psychiatry Fields.
  • Dr. Daly began her academic journey at the University of Minnesota Medical School where she earned a Medical Doctor (M.D.)
  • She then completed an internship in 1993 with Loyola Medicine MacNeal Hospital and finished residencies in pediatrics in 1996 and psychiatry in 1998.
  • The doctor capped her scholarship with a fellowship training in child and adolescent psychiatry in 2000 at the University of Minnesota Medical School.

Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Retrieved on: 
Wednesday, November 1, 2023

CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the third quarter ended September 30, 2023 and provided key pipeline and business updates.

Key Points: 
  • ET
    CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics , (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the third quarter ended September 30, 2023 and provided key pipeline and business updates.
  • Leveraging its deep understanding of neurocircuitry and targeted receptor subtype selectivity, Cerevel is advancing its broad and diverse pipeline of novel neuroscience product candidates.
  • Cerevel is conducting the REALIZE trial, a Phase 2 proof-of-concept trial in focal epilepsy, and a corresponding open-label safety extension trial.
  • ET to discuss its third quarter 2023 financial results and key pipeline and business updates.

Project Healthy Minds Announces Programming for Second-Annual World Mental Health Day Festival at New York’s Hudson Yards

Retrieved on: 
Thursday, September 28, 2023

Project Healthy Minds, a Millennial & Gen Z-driven mental health tech non-profit, announced today the programming for its second-annual World Mental Health Day Festival, taking place Tuesday, October 10 at Hudson Yards in New York City.

Key Points: 
  • Project Healthy Minds, a Millennial & Gen Z-driven mental health tech non-profit, announced today the programming for its second-annual World Mental Health Day Festival, taking place Tuesday, October 10 at Hudson Yards in New York City.
  • This is the world’s largest festival for World Mental Health Day.
  • The festival’s expansive programming slate includes SoulCycle charity rides, Equinox sound bath meditation experiences, and a “community jog” with Emmy Award-winning content creator Timm Chiusano.
  • “This year’s Project Healthy Minds World Mental Health Day Festival is about convening iconic leaders across public policy, media, culture, sports, business, and academia and curating conversations and experiences about the future of mental health in this country,” said Phillip Schermer, Founder & CEO of Project Healthy Minds.

Mental Health Treatment in Houston

Retrieved on: 
Tuesday, August 29, 2023

This strategic collaboration brings together cutting-edge technology and compassionate care, aiming to elevate the standard of mental health treatment.

Key Points: 
  • This strategic collaboration brings together cutting-edge technology and compassionate care, aiming to elevate the standard of mental health treatment.
  • The partnership between Salience and CyFair Psychiatry marks an exciting milestone in the field of mental health.
  • Salience TMS is at the forefront of innovative mental health treatment through TMS Therapy.
  • CyFair Psychiatry offers expert diagnosis and treatment of mental health issues, delivered with understanding and compassion.

Medication can help you make the most of therapy − a psychologist and neuroscientist explains how

Retrieved on: 
Monday, August 28, 2023

As a clinical psychologist and neuroscience researcher, I have been working to integrate insights from both fields to expand treatment options for those suffering from depression, anxiety and related conditions.

Key Points: 
  • As a clinical psychologist and neuroscience researcher, I have been working to integrate insights from both fields to expand treatment options for those suffering from depression, anxiety and related conditions.
  • Anxiety and depression are the most prevalent mental health conditions around the world.
  • Doctors and therapists recommend many patients seeking mental health care try more than one approach simultaneously, such as medication and therapy.

Neuroplasticity and treatment

    • Neuroplasticity refers to the brain’s capacity to flexibly adjust in response to an ever-changing environment – it’s a critical component of learning.
    • Research has shown that many effective biological treatments, including medications and neurostimulation, can enhance or alter neuroplasticity.
    • For both older and newer antidepressant and anti-anxiety medications, relapse rates begin climbing shortly after patients stop treatment.
    • But such learning depends on neuroplasticity to forge and retain these new, helpful pathways in the brain.

Synergies in combined treatment

    • Designing combined treatments to explicitly promote synergy is relatively new, and there is increasing evidence supporting it.
    • D-cycloserine may also enhance the antidepressant effects of a type of neurostimulation called transcranial magnetic stimulation, which stimulates nerve cells using magnetic fields.
    • Researchers think these short-term effects foster new insights and perspectives that psychotherapists can help patients integrate into their permanent worldview.
    • However, it’s important to note that different treatment approaches can occasionally work against each other, lessening the long-term benefits of psychotherapy alone.

Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

Retrieved on: 
Wednesday, August 2, 2023

CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) --  Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the second quarter ended June 30, 2023 and provided key pipeline and business updates.

Key Points: 
  • ET
    CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics , (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the second quarter ended June 30, 2023 and provided key pipeline and business updates.
  • Total research and development expense includes equity-based compensation expense of $7.2 million and $13.6 million for the second quarter and six months ended June 30, 2023, respectively.
  • Total general and administrative expense include equity-based compensation expense of $7.3 million and $13.5 million for the second quarter and six months ended June 30, 2023, respectively.
  • ET to discuss its second quarter 2023 financial results and key pipeline and business updates.

Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031

Retrieved on: 
Wednesday, July 26, 2023

PALM BEACH, Fla., July 26, 2023 /PRNewswire/ -- Psychedelic and hallucinogenic medicines market have been growing consistently over the past several years and are expected to continue to rise in the coming years.  Psychedelic medicines are a group of substances, including chemicals, such as LSD, and plants used to treat multiple mental disorders, including resistant depression, opiate addiction, and panic disorder, among others. This medicine changes and enhances sensory perceptions, thought processes, and energy levels and facilitates favorable experiences.  A recent report from Insight Ace Analytic projected that the Psychedelic Therapeutics Market Size is valued at 3.94 Billion in 2022 and is predicted to reach 13.29 Billion by the year 2031 at a 14.92 % CAGR during the forecast period for 2023-2031.  The report said: "The Global psychedelic therapeutics market is proliferating owing to the increasing incidence of depression cases across the world. Additionally, changed lifestyles and quality of living are supporting the growth of psychedelic medicine market. In addition, the market is anticipated to expand lucratively as a result of the growing need for medicines to treat psychological drug dependency. On the other hand, a greater acceptance of non-therapeutic treatments over allopathic therapies and tight rules implemented by various governments to commercialize psychedelic medications may inhibit the market growth."  Active Companies active today in markets include:  Cybin Inc. (NYSE: CYBN) (NEO: CYBN), COMPASS Pathways plc (NASDAQ: CMPS), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), Seelos Therapeutics, Inc. (NASDAQ: SEEL), Numinus Wellness Inc. (OTCQX: NUMIF) (TSX: NUMI).

Key Points: 
  • A recent report from Insight Ace Analytic projected that the Psychedelic Therapeutics Market Size is valued at 3.94 Billion in 2022 and is predicted to reach 13.29 Billion by the year 2031 at a 14.92 % CAGR during the forecast period for 2023-2031.
  • The report said: "The Global psychedelic therapeutics market is proliferating owing to the increasing incidence of depression cases across the world.
  • Additionally, changed lifestyles and quality of living are supporting the growth of psychedelic medicine market.
  • Worldwide has a track record of successful patient recruitment for psychedelic trials and global relationships with best-in-class investigative sites.